Price$5.10+3.15 (+161.54%)
2026-03-052026-06-08
News · 26 weeks36+67%
2025-12-142026-06-07
Mix2290d
- SEC Filings9(41%)
- Other7(32%)
- Insider5(23%)
- Offering1(5%)
Latest news
25 items- PRBluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027, beyond expected FDA submission; if warrants are exercised in full for cash, it is anticipated that the cash runway would extend well beyond FDA approval and first full year of commercialization ACTON, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on near-patient testing for critical care, today announced the closing of its previously announced private placement for the purchase
- SECSEC Form SCHEDULE 13G filed by Bluejay Diagnostics Inc.SCHEDULE 13G - Bluejay Diagnostics, Inc. (0001704287) (Subject)
- PRBluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules$8.5 million upfront with up to approximately $15.1 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027, beyond expected FDA submission; if warrants are exercised in full for cash, it is anticipated that the cash runway would extend well beyond FDA approval and first full year of commercialization ACTON, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on near-patient testing for critical care, today announced that it has entered into definitive agreements for the purchase and sale of
- SECBluejay Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- PRBluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic PartnershipACTON, Mass. and CARLSBAD, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. ("Bluejay" or the "Company") (NASDAQ:BJDX), a medical diagnostics company focused on near-patient testing for critical care, today announced a strategic partnership with Argonaut Manufacturing Services ("Argonaut") to support the advancement of Bluejay's Symphony™ platform. This partnership is designed to support Bluejay's broader efforts to establish scalable U.S.-based manufacturing capabilities aligned with its ongoing clinical development programs and future commercialization objectives. In addition, the partnership is intended to strengthen Bluejay's future commercial infrastructure by supp
- INSIDERDirector Wurth Douglas Clark bought $25,000 worth of shares (12,500 units at $2.00) (SEC Form 4)4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
- INSIDERPresident and CEO Dey Indranil bought $25,000 worth of shares (12,500 units at $2.00), increasing direct ownership by 56,818% to 12,522 units (SEC Form 4)4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
- INSIDERDirector Chase Donald R bought $25,000 worth of shares (12,500 units at $2.00), increasing direct ownership by 50,000% to 12,525 units (SEC Form 4)4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
- INSIDERDirector Zeidman Fred S bought $25,000 worth of shares (12,500 units at $2.00) (SEC Form 4)4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
- INSIDERDirector Dey Svetlana bought $25,000 worth of shares (12,500 units at $2.00), increasing direct ownership by 1,250,000% to 12,501 units (SEC Form 4)4 - Bluejay Diagnostics, Inc. (0001704287) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Bluejay Diagnostics Inc.SCHEDULE 13G/A - Bluejay Diagnostics, Inc. (0001704287) (Subject)
- SECSEC Form 10-Q filed by Bluejay Diagnostics Inc.10-Q - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- SECBluejay Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- PRBluejay Diagnostics Provides First Quarter 2026 Corporate UpdateACTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient outcomes in critical care settings, today provided a corporate update highlighting progress achieved during the first quarter of 2026 and recent operational developments related to its Symphony™ near-patient diagnostic platform. During the first quarter of 2026, Bluejay continued advancing the clinical, manufacturing, and regulatory activities supporting the development of its Symphony IL-6 test for sepsis patient monitoring and risk assessment in critical care settings. Q1 2026 and Recent Highlights • Continued enrollment prog
- SECSEC Form DEF 14A filed by Bluejay Diagnostics Inc.DEF 14A - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- SECSEC Form PRE 14A filed by Bluejay Diagnostics Inc.PRE 14A - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- SECBluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- PRBluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical TrialACTON, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. ("Bluejay" or the "Company"), a medical diagnostics company focused on rapid, near-patient testing, today announced the successful enrollment of 624 patients in its ongoing SYMON-II Trial, a pivotal clinical study evaluating the Company's Symphony™ platform for interleukin-6 (IL-6) testing in critical care settings to determine patient acuity for sepsis triage and monitoring. The SYMON-II study has a target enrollment of 750 patients, and the Company expects to complete enrollment within the next 2 to 3 months, subject to site activity and patient flow. Importantly, the study's inclusion and exclusion criteria hav
- SECBluejay Diagnostics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- SECBluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- SECBluejay Diagnostics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- PRBluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual MeetingACTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid near-patient tests for critical care conditions, today announced that an abstract related to its Symphony™ IL-6 Test has been accepted for presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting, which will take place May 18–21, 2026 in Atlanta, Georgia. The presentation will report findings from SYMON-I, a multicenter pilot clinical study evaluating interleukin-6 (IL-6) levels in patients with sepsis who were admitted or intended for admission to the intensive care unit (ICU). The analysis evalu
- SECSEC Form 10-K filed by Bluejay Diagnostics Inc.10-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- SECBluejay Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Bluejay Diagnostics, Inc. (0001704287) (Filer)
- PRBluejay Diagnostics Provides Corporate Update and 2026 Strategic OutlookACTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid near-patient tests to improve patient outcomes in critical care settings, today provided a corporate update highlighting recent progress and its planned strategic trajectory through 2026. Operational and Clinical ProgressBluejay continues to advance its Symphony™ platform, including the Company's lead product candidate for the rapid measurement of Interleukin-6 (IL-6) to support sepsis risk assessment and critical-care decision making. The Company confirmed that its SYMON™ II clinical study is progressing as planned, with on
BJDX FAQ
7 questionsWhat does Bluejay Diagnostics Inc. do?
Bluejay Diagnostics, Inc., an in-vitro diagnostic company, develops, manufactures, and markets minimally invasive point-of-care (POC) diagnostics tests and devices for infectious disease, inflammation, and oncology markets in the United States. It is developing Symphony biomarker detection platform for the detection of sepsis, cancer, cardiac ishcemia, and congestive heart failure. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. It has a collaboration agreement with Toray Industries, Inc. to develop a point of care test for covid-19...Where does BJDX stock trade?
Bluejay Diagnostics Inc. (BJDX) is listed on NASDAQ.What sector and industry is BJDX in?
Bluejay Diagnostics Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Bluejay Diagnostics Inc. go public?
Bluejay Diagnostics Inc. (BJDX) completed its IPO in 2021.What are analysts saying about BJDX?
Bluejay Diagnostics Inc. has had 1 recent analyst action on file. The most recent action was from Dawson James: Buy with a $1000.00 price target on 2022-01-12. Recent price targets cluster around $1000.00.What companies are similar to BJDX?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare BJDX side-by-side with any of them on Quantisnow.How can I track BJDX on Quantisnow?
Quantisnow aggregates Bluejay Diagnostics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BJDX to receive live email and push alerts on every new disclosure.